Amgen Reports the P-III (MITIGATE) Study Data of Uplizna (Inebilizumab-cdon) to Treat Immunoglobulin G4-Related Disease (IgG4-RD)
Shots:
- The P-III (MITIGATE) trial assesses the safety & efficacy of Uplizna (300mg, IV) vs PBO to decrease the flares risk in IgG4-RD adults (n=135)
- The study met 1EP, depicting reduced risk of IgG4-RD flare by 87% at 52wks. plus reached the 2EPs of annualized flare rate; flare-free, treatment-free & flare-free, corticosteroid-free complete remission without any new safety signals. Full data will be highlighted at upcoming conferences
- Additionally, the study was carried out in collaboration with Mitsubishi Tanabe Pharma, marketing authorization holder in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, Philippines, Singapore, and Taiwan and Hansoh Pharma, exclusive licensee in mainland China, Hong Kong & Macau
Ref: Amgen | Image: Amgen
Related News:- Horizon’s Uplizna (inebilizumab) Receives EC’s Approval for the Treatment of Neuromyelitis Optica Spectrum Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
